메뉴 건너뛰기
British Medical Journal
Volumn 332, Issue 7555, 2006, Pages 1423-1425
Value of sentinel node status as a prognostic factor in melanoma: Prospective observational study
Author keywords

[No Author keywords available]
Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; LYMPHADENECTOMY; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME; DISEASE FREE SURVIVAL; INCIDENCE; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSPECTIVE STUDY; SCINTISCANNING; SKIN TUMOR; TUMOR RECURRENCE; UNITED KINGDOM; VALIDATION STUDY;
EID: 33745293107     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38849.680509.AE     Document Type: Article
Times cited : (57)
References (7)
  • 1
    • 27944452869 scopus 로고    scopus 로고
    • Postoperative arm morbidity and quality of life: Results of the ALMANAC randomised sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer
    • Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, et al. Postoperative arm morbidity and quality of life: results of the ALMANAC randomised sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2005;15:1-15.
    • (2005) Breast Cancer Res Treat , vol.15 , pp. 1-15
    • Fleissig, A.1    Fallowfield, L.J.2    Langridge, C.I.3    Johnson, L.4    Newcombe, R.G.5    Dixon, J.M.6
  • 2
    • 24044509861 scopus 로고    scopus 로고
    • Interim results of the multicenter selective lymphadenectomy trial (MSLT-I) in clinical stage I melanoma
    • abstract 7500
    • Morton DL, Thompson JF, Cochran AJ, Essner R, Elashoff R. Interim results of the multicenter selective lymphadenectomy trial (MSLT-I) in clinical stage I melanoma. J Clin Oncol 2005;23:16S, abstract 7500.
    • (2005) J Clin Oncol , vol.23
    • Morton, D.L.1    Thompson, J.F.2    Cochran, A.J.3    Essner, R.4    Elashoff, R.5
  • 3
    • 0032977814 scopus 로고    scopus 로고
    • Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
    • Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976.
    • (1999) J Clin Oncol , vol.17 , pp. 976
    • Gershenwald, J.E.1    Thompson, W.2    Mansfield, P.F.3    Lee, J.E.4    Colome, M.I.5    Tseng, C.H.6
  • 4
    • 14544267180 scopus 로고    scopus 로고
    • Sentinel lymphadenectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanoma
    • Kretschmer L, Beckmann I, Thoms KM, Haenssle H, Bertsch HP, Neumann CH. Sentinel lymphadenectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanoma. Eur J Cancer 2005;41:531-8.
    • (2005) Eur J Cancer , vol.41 , pp. 531-538
    • Kretschmer, L.1    Beckmann, I.2    Thoms, K.M.3    Haenssle, H.4    Bertsch, H.P.5    Neumann, C.H.6
  • 5
    • 25844465690 scopus 로고    scopus 로고
    • Post-surgery adjuvant therapy with intermediate doses of interferon alpha 2 beta versus observation in patients with stage 11b/111 melanoma (EORTC 19852): Randomised controlled trial
    • Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alpha 2 beta versus observation in patients with stage 11b/111 melanoma (EORTC 19852): randomised controlled trial. Lancet 2005;366:1189-96.
    • (2005) Lancet , vol.366 , pp. 1189-1196
    • Eggermont, A.M.1    Suciu, S.2    MacKie, R.3    Ruka, W.4    Testori, A.5    Kruit, W.6
  • 6
    • 0030030347 scopus 로고    scopus 로고
    • Interferon alpha 2 b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
    • Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha 2 b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7-17.
    • (1996) J Clin Oncol , vol.14 , pp. 7-17
    • Kirkwood, J.M.1    Strawderman, M.H.2    Ernstoff, M.S.3    Smith, T.J.4    Borden, E.C.5    Blum, R.H.6
  • 7
    • 0034088027 scopus 로고    scopus 로고
    • High and low dose interferon alpha 2 beta in high risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
    • Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS. High and low dose interferon alpha 2 beta in high risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
    • (2000) J Clin Oncol , vol.18 , pp. 2444-2458
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sondak, V.K.3    Richards, J.4    Flaherty, L.E.5    Ernstoff, M.S.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.